Key result
Novel nanomedicine MTCA-KKV shows ~1,670-fold greater antithrombotic potency than aspirin in preclinical arterial thrombosis models.
Why the study?
Because MTCA-KKV adheres to activated platelets and targets P-selectin and GPIIb/IIIa in vitro, it was developed and evaluated as a thrombus-targeting nano-medicine.
Does oral nano-scaled MTCA-KKV target thrombus, inhibit arterial thrombosis, and dissolve blood clots in vivo in rat models compared to normal saline, MTCA, aspirin, and urokinase?
Does oral nano-scaled MTCA-KKV target thrombus, inhibit arterial thrombosis, and dissolve blood clots in vivo in rat models compared to normal saline, MTCA, aspirin, and urokinase?
MTCA-KKV self-assembles into nanoparticles (<70 nm in plasma) that selectively adhere to platelets, downregulate GPIIb/IIIa and P-selectin, and exclusively penetrate thrombi to release anti-thrombotic and thrombolytic pharmacophores in rats.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for oral nano-thrombolytics; leaves open translation to human arterial thrombosis.
BACKGROUND: In vitro (1R,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val (MTCA-KKV) adheres activated platelets, targets P-selectin and GPIIb/IIIa. This led to the development of MTCA-KKV as thrombus targeting nano-medicine. METHODS: MTCA-KKV was characterized by nano-feature, anti-thrombotic activity, thrombolytic activity, thrombus target and targeting release. RESULTS: In vivo 0.01 μmol/kg of MTCA-KKV formed nano-particles less than 100 nm in diameter, targeted thrombus, released anti-thrombotic and thrombolytic pharmacophores, prevented thrombosis and dissolved blood clots. CONCLUSION: Based on the profiles of targeting thrombus, targeting release, inhibiting thrombosis and dissolving blood clots MTCA-KKV is a promising nano-medicine.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2019) studied Arterial thrombosis and blood clots (preclinical rat models). MTCA-KKV ((1R,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val) vs. Normal saline (3 mL/kg oral), MTCA (1 μmol/kg oral), aspirin (167 μmol/kg oral), and urokinase (20,000 IU/kg IV) was evaluated on Arterial thrombus weight (anti-thrombotic activity) and decrease in cylindrical thrombus weight (thrombolytic activity) (p=<0.05). Oral MTCA-KKV at a minimal effective dose of 0.01 μmol/kg formed <100 nm nanoparticles that significantly inhibited arterial thrombosis (1,670-fold more potent than aspirin) and dissolved blood clots in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: